Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. ( CLDX ) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria September 22, 2026 8:00 AM EDT Company Participants Sarah Cavanaugh - Senior Vice President of Corporate Affairs & Administration Anthony S. Marucci - Founder, President, CEO & Director Diane Young - Senior VP & Chief Medical Officer Teri Lawver - SVP & Chief Commercial Officer Margo Heath-Chiozzi - Senior Vice President of Regulatory Affairs Tibor Keler - Founder, Chief Scientific Officer & Executive VP Conference Call Participants Nathanael Charoensook - Leerink Partners LLC, Research Division Yaron Werber - TD Cowen, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Judah Frommer - Morgan Stanley, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Omotolani Uthman - Goldman Sachs Group, Inc., Research Division Gustave Diep - Barclays Bank PLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Celldex Therapeutics webcast. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sarah Cavanaugh. Please go ahead. Sarah Cavanaugh Senior Vice President of Corporate Affairs & Administration Thank you. Good morning, and thank you for joining us. We're very excited to start our day discussing positive top line results from our 2 Phase III studies in chronic spontaneous urticaria, EMBARQ-CSU1 and EMBARQ-CSU2. In addition to being available on the webcast portal, the accompanying slides for this morning's call are also on the Investor Relations page of our website in the Events section. Joining me on the call this morning are Anthony Marucci, Co-Founder, President and Chief Executive Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Teri Lawver, Senior Vice President and Chief Commercial